Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01941511 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01941511: Completed Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT01941511 is a Phase 1 study that has completed, run by GlycoMimetics Incorporated. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01941511, a Phase 1 study, has completed, sponsored by GlycoMimetics Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of GMI-1070 in African-American Adult subjects. This is conducted as part of standard drug development.
Interventions
- DRUG Rivipansel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01941511
The ClinicalTrials.gov registry entry for NCT01941511 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivipansel is the first listed.
NCT01941511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01941511 about?
NCT01941511 is a clinical study titled "A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects". This is a clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of GMI-1070 in African-American Adult subjects. This is conducted as part of standard drug development.
What is the current status of trial NCT01941511?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01941511?
The interventions under investigation include: Rivipansel (DRUG).
Who is sponsoring clinical trial NCT01941511?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.